Active ingredientBoceprevirCat. No. P-B095-001CAS 394730-60-0Family · Pharmaceutical analytical standards
Boceprevir
An inhibitor of the NS3 protease of the hepatitis C virus, approved in the United States in 2011 for genotype 1 together with peginterferon and ribavirin; it left the market in 2015, with the arrival of the new direct-acting antivirals. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It is structurally related to nirmatrelvir, the oral antiviral developed against COVID-19: both block a protease the virus needs in order to replicate.
Go to the active ingredient →Active ingredientBoceprevirCat. No. P-B095-001CAS 394730-60-0
Isotopically labelledBoceprevir-d9Cat. No. P-B095-002CAS 1256751-11-7
ImpurityBoceprevir Impurity 1Cat. No. P-B095-003CAS 943516-56-1
ImpurityBoceprevir Impurity 2Cat. No. P-B095-004CAS 1684446-84-1
ImpurityBoceprevir Dimer ImpurityCat. No. P-B095-005No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.